Biomedical applications of polyelectrolyte coated spherical gold nanoparticles by Fuller, Melanie A & Köper, Ingo
Fuller and Köper  Nano Convergence            (2019) 6:11  
https://doi.org/10.1186/s40580-019-0183-4
REVIEW
Biomedical applications of polyelectrolyte 
coated spherical gold nanoparticles
Melanie A. Fuller and Ingo Köper* 
Abstract 
Surface modified gold nanoparticles are becoming more and more popular for use in biomaterials due to the pos-
sibility for specific targeting and increased biocompatibility. This review provides a summary of the recent literature 
surrounding polyelectrolyte coatings on spherical gold nanoparticles and their potential biomedical applications. The 
synthesis and layer-by layer coating approach are briefly discussed together with common characterisation methods. 
The potential applications and recent developments in drug delivery, gene therapy, photothermal therapy and imag-
ing are summarized as well as the effects on cellular uptake and toxicity. Finally, the future outlook for polyelectrolyte 
coated gold nanoparticles is explored, focusing on their use in biomedicine. 
Keywords: Polyelectrolyte, Gold nanoparticles, Nanoparticles, Gold, Biomedical
© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
1 Introduction
Gold nanoparticles (AuNPs) can be described as solid 
gold particles with a diameter between 1 and 100  nm, 
and have the potential to be used in a range of bio-
medical applications due to their unique physical and 
optical properties [1–4]. Examples of these unique 
properties include the surface plasmon resonance (SPR) 
effect, which can give information about the local par-
ticle environment as well as the physical dimensions of 
the particles. Furthermore, by employing the Surface 
Enhanced Raman Scattering (SERS), AuNPs can be used 
as probes to enhance Raman scattering applications [5–
8]. After a typical synthesis, AuNPs are coated with an 
organic material or capping agent which provides stabil-
ity to the particles. One of the advantages of AuNPs is 
that they can be easily functionalized with a range of dif-
ferent materials including antibodies, proteins, ligands, 
DNA, polymers and polyelectrolytes [9–11]. This ease of 
functionality is useful in many of the biomedical applica-
tions which are discussed here.
Polyelectrolytes (PEs) are polymers of repeating units 
which contain an ionizable group [12]. These charged 
polymers can be used to coat surfaces and particles in a 
number of ways including covalent attachment, hydro-
gen bonding and electrostatic interactions between layers 
[13, 14]. While there are many ways PEs can be attached 
to nanoparticles (NPs), this review will focus on the elec-
trostatic attachment of PE coatings as they are easy to 
produce and have a range of applications from micro-
fluidics to water membrane filtration systems [14, 15]. 
Specifically, the Layer-by-layer (Lbl) approach will be 
reviewed, where PEs can be attached to a surface in a sin-
gle or multilayer deposition. Essentially the Lbl electro-
static approach uses two solutions of opposite charge. A 
substrate can be dipped into a solution or a particle solu-
tion can be mixed with PEs to coat a surface (Fig. 1) [16, 
17]. Once a coating of the polyelectrolyte has been added, 
the charge on the substrate or particle is inverted, and 
hence a subsequent polymer layer of opposite charge can 
be applied. The number of layers applied determines the 
total thickness of the polymer coating [13]. Due to the 
ease of deposition, Lbl polyelectrolyte coatings have been 
initially investigated on flat substrates for a wide range 
of applications, but now the coating of 3-dimensional 
objects is also being explored [15, 18, 19]. These objects, 
such as spherical nanoparticles, offer larger surface area 
to volume ratios and larger reactive surface areas, which 
is essential in drug delivery and catalysis [20, 21].
The coating efficiency of the PEs on NPs is influenced 
by the shape of the nanoparticle, the type, length and 
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concentration of the polymer, as well as the total salt con-
centration in the solution used [22, 23]. Gold nanorods 
(GNRs) have been the most widely studied 3D particle 
shape for PE coatings, as their structure allows for rela-
tively homogeneous coatings. Additionally, they have been 
extensively used in sensing applications, as their surface 
plasmon is particularly sensitive to changes in the local 
environment [20, 24–27]. This review however is focused 
on exploring spherical AuNPs, and comprehensive reviews 
of AuNRs can be found elsewhere [28, 29]. The curved sur-
face of small (< 50 nm) NPs makes it difficult to form com-
plete and homogeneous coatings, in part due to the lack of 
flexibility of the polymer chains, resulting in poor coverage 
on the nanoparticle surface and a decrease in stability of 
the coating [30]. In general, incomplete coatings can cause 
particle aggregation [23, 31, 32]. To avoid incomplete coat-
ings, the polymer which is coating the NP needs to be in 
excess to ensure complete coverage on the surface [23]. 
Similarly the addition of salt in the coating solution typi-
cally allows for more flexibility in the PE chains, which can 
lead to an improved coverage of the particles [22, 33–35].
2  Synthesis of polyelectrolyte coated 
nanoparticles
There are many different approaches to synthesizing 
AuNPs, each aiming to control nanoparticle size, shape 
and surface functionality [36–38]. In the Turkevich 
method, hydrogen tetrachloroaurate  (HAuCl4) is 
treated with citric acid in boiling water, with the citrate 
acting both as a reducing and stabilizing agent [39, 40]. 
This method produces NPs with diameters in the range 
of 10–20  nm, with the particle size being controlled 
by the gold to citrate ratio [41]. Alkanethiol-stabilized 
AuNPs, which are soluble in organic solvents, can be 
formed using tetraoctylammonium bromide (TOAB) as 
the capping agent and sodium borohydrate  (NaBH4) as 
the reducing agent [42]. Depending on the gold-to-thiol 
ratio, temperature and reduction rate, NPs between 1.5 
and 5 nm in diameter can be produced [42]. Other syn-
thesis methods resulting in size and particle uniform-
ity distributions use different reducing agents such as 
sucrose, ethylenediaminetetraacetic acid, fruit extracts 
and amines [43–47].
The capping agent used in the NP synthesis influ-
ences which PE can be used for the initial coating. The 
Lbl technique is based on the attraction of oppositely 
charged layers and is the main interaction employed in 
coating AuNPs with PEs. Commonly used PE polymers 
are shown in Table 1. The charge of the PE is important 
as the polymer will electrostatically attach to a particle 
only if the capping agent is of opposite charge [14]. For 
example, after the Turkevich method which caps the 
particles in negatively charged citrate, only positively 
charged PEs will attach.
Fig. 1 Method for self-assembly of polyelectrolyte-coated citrate capped gold nanoparticles using the Lbl method
Table 1 Commonly used polyelectrolytes showing their charge at pH 7 and their current applications
Abbreviation Name Charge at neutral pH Application References
PEI Polyethyleneimine Positive Gene therapy, drug delivery [48, 49]
PAH Polyallylamine hydrochloride Positive Drug delivery, gene therapy [50, 51]
PSS Polystyrene sulfonate Negative Drug delivery [52, 53]
PLL Poly-l-lysine Positive Gene therapy [54]
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3  Characterising the attachment 
of polyelectrolytes onto gold nanoparticles
Typically, the attachment of PE coatings on AuNPs is 
characterized using Surface Plasmon Resonance (SPR), 
Dynamic Light Scattering (DLS) and zeta potential. 
Other methods such as Transmission Electron Micros-
copy (TEM) and Nuclear Magnetic Resonance (NMR) 
are commonly used but will not be discussed here.
3.1  Surface plasmon resonance
A surface plasmon is a charge-density oscillation phe-
nomenon, which exists at the interface of two media with 
dielectric constants of opposite signs [55]. Nobel met-
als have a negative dielectric constant and are therefore 
ideal materials for surface plasmon detection. When 
light of a specific wavelength interacts with a AuNP, it 
causes a collective oscillation of the free electrons in the 
metal [56]. When the incoming electromagnetic wave 
has the same wavevector as the oscillating conduction 
electrons, resonance occurs (Fig.  2) and the incoming 
energy is absorbed into the plasmon wave. Typically, SPR 
is observed by measuring the absorbance of the NP-con-
taining solution as a function of wavelength. The result-
ing signal depends on the shape, size, surface ligand, 
solvent, temperature and proximity of other NPs in the 
solution [57, 58]. For example, spherical AuNPs exhibit 
size dependent absorption peaks (surface plasmon band) 
from 500 to 550 nm [11, 59].
Aggregation of NPs can be observed by a red-shifting 
and broadening of the SPR peak, and the colour of the 
NP solution changes from a red to blue due to interpar-
ticle plasmon coupling [60]. The addition of a polymer 
layer onto the surface of the AuNP results in a change 
in the dielectric properties at the nanoparticle surface 
which shifts the SPR peak (Fig. 3a, b) [30]. As each poly-
mer layer is added, the peak’s wavelength increases as the 
dielectric property changes. Due to this, the Lbl addition 
of PE multilayer architectures can be monitored through 
changes in the NPs SPR peak (Fig. 3a).
3.2  Zeta potential
Measuring the zeta potential of AuNPs is a quick and 
efficient way to determine the charge of the particles and 
the stability of the colloidal system [62]. The zeta poten-
tial can be described as the potential at the shear plane of 
a solid particle moving under an electric field, where the 
shear plane is the boundary at the solid–liquid interface, 
between the stationary and diffuse layers [63, 64]. At neu-
tral pH, citrate capped AuNPs have a resulting negative 
charge, which attracts positively charged electrolyte ions. 
These ions then form an electrical layer at the surface of 
the particle, known as the Stern layer. A secondary layer 
called the diffuse layer also forms, which consists of both 
positive and negative ions with a high counter-ion charge. 
Together these two layers make up an electrical double 
layer. The zeta potential of the particle corresponds to the 
amount of energy required to shear a particle and asso-
ciated double layer from the bulk solution. In order to 
calculate the zeta potential, the electrophoretic mobility 
of a particle is measured in a direct current electric field 
[62]. Stable colloidal solutions typically have zeta poten-
tials smaller than − 30 mV or larger than + 30 mV. Val-
ues between these potentials indicate unstable solutions, 
as the particles do not carry enough charge to repel each 
other, which can lead to aggregation [65]. In the case of 
PE-coated NPs, the charge of the coated particles alter-
nates between a positive and negative charge, depending 
on the polymers used (Fig. 3c). This process is often used 
to show attachment of the polyelectrolyte layer, as well as 
to confirm the colloidal stability of the system.
4  Uptake and interaction with cells
Biocompatibility is essential in any biomedical appli-
cation as well as the ability for the uptake of NPs into 
cells, especially for applications such as drug delivery. 
Fig. 2 Schematic representation of the conduction electrons oscillating across the gold nanoparticle in the electromagnetic field of incident light
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The interactions of the particle with the cell membrane 
is ultimately what determines cellular uptake, as it is the 
key to the regulation of the uptake process [66]. Cellu-
lar interactions and cellular uptake is a large and com-
plex topic area and hence, this section will only discuss 
the main considerations with select examples. More in-
depth explanations in this area can be found in other 
review articles [67, 68]. The cellular uptake of AuNPs is 
dependent on the size, charge and surface properties of 
the NP [69]. Other biological factors include the type of 
cell, cellular recognition and the temperature [70]. These 
biological factors also affect the protein corona, which is 
a protein layer attached to the AuNP, brought about by 
the proteins found in the body (in vivo) and in serum (in 
vitro) which attach to the NPs surface [70].
There are five ways in which mammalian cells can 
internalize nanoparticles: phagocytosis, macropinocy-
tosis, clatherin-mediated, caveolin-mediated and clath-
erin/cavoelin-independent endocytosis [71–74]. Of these 
pathways, clatherin and caveolin mediated endocytosis 
are often widely grouped as receptor mediated endocyto-
sis [66, 75–77]. It has been proposed that receptor medi-
ated endocytosis is the primary mechanism for cellular 
entry of AuNPs less than 100 nm in diameter into mam-
malian cells [67, 78]. In receptor mediated endocytosis, 
NPs which have ligands on their surface that target spe-
cific receptors, attach to the cells by receptor–ligand 
binding. The membrane of the cell then wraps around the 
NP, internalizing it into the cell. The kinetics of this pro-
cess depend on the size of the NP, with generally a faster 
uptake for larger NPs [70, 78]. However, the size and 
uptake will change depending on the protein corona and 
its composition when it forms around the particle. The 
addition of serum to in vitro essays provides a more real-
istic biological environment, as the proteins in the serum 
can attach to the NP forming the protein corona. This 
corona prevents the NP from having direct contact with 
the cell membrane, hence altering the uptake. The uptake 
rate is determined by the receptor diffusion kinetics and 
the thermodynamic driving force for the membrane 
wrapping [78]. This rate was shown to be dependent on 
the cell type, particle size and the composition of the pro-
tein corona.
Fastest cell uptake has been shown for NPs with diam-
eters of around 55 nm. The chemical energy released by 
the receptor–ligand interaction produces enough free 
energy (thermodynamic driving force) to drive the NP 
into the cell [78–80]. For NPs smaller than 40  nm in 
diameter, the receptor–ligand interactions cannot pro-
vide enough energy to ‘wrap’ the NP on the cell’s surface 
Fig. 3 A UV–Vis spectra of mercaptoundecanoic acid coated AuNPs (dashed line) subsequently coated in (a) Polydiallyldimethylammonium 
chloride (PDADMAC) and (b) PDADMAC/polystyrenesulfonate (PSS). Reproduced from Ref. [61] with permission from Wiley. B Surface plasmon 
band shifts compared to the number of polyelectrolyte coatings on the AuNPs. Reproduced from Ref. [52] with permission from Wiley. C Zeta 
potential of uncoated citrate capped AuNPs (0) then subsequent addition of positively charged polyallylamine (PAA) and negatively charged 
polystyrenesulfonate (PSS). Reproduced and adapted from Ref. [52] with permission from Wiley
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as there are fewer ligands that can interact with recep-
tors, and not enough chemical energy is produced to 
overcome the more unfavorable deformation of the cell 
membrane [80]. In order for smaller NPs to be taken into 
the cell, clusters of NPs are required to overcome the 
energy barrier to internalization [78]. However, when 
taking into account the protein corona, for 50 nm diame-
ter AuNP in serum, the presence of the corona decreased 
the uptake efficiency significantly, with a 70% decrease in 
RAW 264.7 cells (model mouse macrophage cells) and a 
40% decrease in Hep G2 cells (human liver cancer cells). 
For 20 nm and 5 nm AuNP, it was found the inhibitory 
effect of the corona on cellular uptake becomes negligi-
ble for both types of cells [70]. Even with a considerably 
lower uptake efficiency, the uptake was still higher in 
larger (50 nm) AuNP, suggesting for biomedical applica-
tions, ≥ 50 nm AuNPs should be used [70].
The influence of the surface charge on cellular uptake 
is relatively well understood, but also dependant on a 
number of experimental factors. These experimental fac-
tors, including particle size, surface functionalisation, NP 
shape and cell type are often observed to interplay with 
each other, making identifying differences of one vari-
able a complex endeavour. Typically, positively charged 
NPs are more easily taken up by the cell, probably due to 
being attracted by the negatively charged cell membrane 
[81–83]. However, proteins from the growth serum of 
cells can absorb to both cationic and anionic particles, 
forming a protein corona which has the potential to alter 
their charge and thus minimizes attractive forces [84, 85]. 
The effect of proteins adsorbing onto AuNPs has been 
observed through numerous studies including absorb-
tion on curcumin-functionalized AuNP where the uptake 
in human prostate cancer cells was decreased when cur-
cumin-AuNP were in the presence of serum containing 
media compared to serum-free media [86].
The localization of the NP inside the cells is important 
for biomedical applications but once again the intracel-
lular distribution of AuNPs depends on a number of 
factors including size, concentration, and serum/media 
type. NPs with no specific surface functionalisation and 
a diameter of less than 6  nm have been shown to enter 
the nucleus of various cells [87–89]. Similarly, other stud-
ies have observed that diameters of greater than 6 nm do 
not enter the nucleus but often enter cells inside vesicles 
[78, 90–92]. Knowing the size range of NPs which reach 
the nucleus is important for inducing apoptosis in cells 
when treating conditions such as cancer and therefore, 
needs to be taken into consideration depending on the 
application.
The biodistribution of AuNP when injected into mice, 
was observed to change depending on the charge of a 
2 nm core AuNP [93]. Although the research did not use 
PEs to alter the charge, similar results would be expected 
when using PEs. It was found that positively charged NPs 
accumulate in the filtering regions of the spleen and liver, 
indicating they filter from the bloodstream at a faster rate 
than anionic or neutral NPs. The neutral NPs were shown 
to accumulate in the arteries and negatively charged NPs 
were found homogenously distributed within the kidney. 
Another key difference was the neutral NPs which were 
shown to interact with the immune system. This interac-
tion however, may be due to the type of proteins which 
make up the corona surrounding the particle [93].
In terms of PE coated AuNP, there was very little 
research found surrounding the uptake and cellular inter-
actions. Thus, the majority of uptake and interaction 
research has come from studies on AuNP with a large 
variety of coatings. When comparing experiments for 
AuNPs, despite it being such a large research area, it is 
difficult to form conclusions for in vitro studies, as there 
are many complex parameters which dictate the cellular 
response. The cell type, serum used, AuNP size, concen-
tration and charge among others can alter the outcome 
significantly. Similarly another difficulty is being able to 
predict the biodistribution as the protein corona which 
forms when the NPs enter the body, (i.e. blood, lung 
etc.) changes as the NP is transported through different 
regions such as the bloodstream [93]. Overall the uptake 
and distribution is a complex interplay between different 
experimental factors which makes drawing direct com-
parisons difficult.
5  Applications
The unique optical and physical properties of AuNPs and 
the increased biocompatibility of PE-coated nanopar-
ticles has led to a range of potential biomedical applica-
tions, including drug delivery, gene therapy and cancer 
therapy (Table 1) [50, 52, 53, 69, 94]. The type of PE used 
has a significant influence on the usage of particles and 
the interaction of particles with tissues and cells. A fun-
damental understanding of the influence of the PEs on 
interactions with biological material is hence crucial to 
optimize their use. There are two main delivery methods 
for drug delivery: targeted and non-targeted. In targeted 
delivery, a ligand, generally an antibody or peptide, is 
attached to the NP and will target a receptor on a specific 
cell [95, 96]. Non-targeted delivery is the delivery without 
targeting specific cells, where the drug will be released 
to both healthy and diseased cells. The type of delivery is 
extremely important in applications such as gene therapy 
and photothermal therapy, where treatment needs to be 
given into a specific area of the body. siRNA delivery for 
example will target a specific cell’s cytoplasm to achieve 
down-regulation (80–90% decrease) of an overproduced 
protein [97]. Similarly in photothermal therapy, ensuring 
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the AuNPs reaches the diseased cells to cause cell death 
rather than healthy cells is vital to reduce collateral dam-
age [98].
5.1  Drug delivery
Targeted drug delivery allows for an increased concentra-
tion of drug to be given to a specific cell type compared 
to conventional untargeted delivery. In many cases this 
higher concentration increases the efficacy and decreases 
unwanted side effects, especially useful for drugs that can 
have debilitating side effects such those used in chemo-
therapy. Attaching ligands such as antibodies to the sur-
face of a drug carrier allows drug release into specific 
cells which have the correct receptors.
For targeted drug delivery, PE coatings can be used 
as anchoring points for antibodies. This was shown in a 
proof of concept study, where IgG monoclonal antibod-
ies, which target proteins overexpressed in cancer cells, 
were anchored to the surface of polyallylamine (PAA) 
and PSS coated AuNPs (Fig.  4) [52]. Conceptually, this 
could have great implications for the cancer treatments, 
as drugs could be loaded inside the AuNP or within the 
PE layers and then be targeted to cancer cells by the anti-
body attached on its surface. This would mean a lower 
dose of chemotherapy could be given with less systemic 
exposure, lessening the side effects and increasing the 
survival rate. Issues, however, with this type of antibody 
targeting is the administration into the body, where 
unlike an in  vitro test there are many proteins which 
attach themselves to foreign bodies like NPs, making the 
receptor to antibody attachment problematic.
One of the advantages of the PE systems is that water 
insoluble drugs, which previously have been difficult to 
deliver, now have an easier pathway [99]. This is shown 
to be possible through the use of multilayer based drug 
carrier systems, where a vehicle such as a NPs can have 
water-insoluble drugs encapsulated within its PE chains. 
In a proof of concept study, three polymer layers with one 
containing a water-insoluble drug, were absorbed onto a 
NP carrier and this carrier was able to increase the drug 
deposition efficiency by a factor of 100 [53]. In order 
to trap the drug, citrate coated AuNPs were used, then 
subsequently coated with polyallylamine hydrochloride 
(PAH) before the complexed drug was mixed with PSS 
and electrostatically attached to the PAH coating.
A more recent proof of concept study has found that 
the drug, Imatinib Mesylate (IM), used for cancer treat-
ment could be encapsulated into PSS/PEI multilayer 
functionalized gold nanoparticles (Fig.  5). This IM-PSS/
PEI-AuNP system was tested in several ways with uptake 
into B16F10 murine melanoma cells measured as well as 
an in vitro skin penetration study [48]. At a gold concen-
tration greater than 50 μM and IM concentrations above 
31 μM, the IM-PSS/PEI-AuNP had a significantly higher 
growth inhibition of cancer cells compared to IM alone. 
The in vitro skin penetration studies conducted using pig 
ear skin, showed the use of iontopherisis (voltage gra-
dient on the skin) enhanced the skin penetration of the 
IM-PSS/PEI-AuNPs. Thus a topical treatment of IM-
PSS/PEI-AuNPs with iontopheresis shows potential for 
enhanced melanoma treatement compared to IM alone.
5.2  Gene therapy
Small interfering RNA (siRNA) delivery has the potential 
to be used in therapeutics to temporarily silence genes 
which could have significant effects on genetic diseases, 
Fig. 4 Citrate stabilized gold nanoparticles coated with PSS and PAA 
in a Lbl method with the addition of IgG antibody through amide 
linkages. Reproduced from Ref. [52] with permission from Wiley
Fig. 5 A schematic of the cancer drug, Imatinib Mesylate being 
encapsulated in the multilayer coated PEI/PSS/PEI AuNPs, showing 
the use of iontopherisis for topical delivery into the layers of the skin. 
Reprinted from Ref. [48] with permission from the American Chemical 
Society
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however siRNA are notoriously difficult to deliver due to 
instability [100]. PE coated AuNPs have been shown to 
be better delivery vehicles than commonly used polymer 
vehicles [49]. Other delivery platforms such as cationic 
lipids and polymers have shown promise however insta-
bility is often the biggest issue, leading to decreases in 
efficacy [69]. In a proof of concept study, siRNA has been 
attached onto a PE coated AuNP system and delivered 
into CHO-K1 cells (hamster ovary cells) which express 
enhanced green fluorescent protein (EGFP) [69]. The 
siRNA successfully reduced the EGFP expression and the 
cells remained viable after the addition of the AuNPs.
The current gold standard for non-viral gene transfec-
tion is using PEI or Lipofectamine. PEI is a polyelectro-
lyte in its own right, however, in this case, it is used to 
form a polyplex with DNA, rather than as a coating. This 
gold standard has been recently challenged in a study 
which synthesized PEI (25  kDa) coated AuNP as DNA 
nanocarriers which found that these nanoparticles were 
more efficient gene vectors than both Lipofectamine 
and un-modified PEI [49]. PEI coated nanoparticles also 
showed low cell cytotoxicity and were fabricated in a sim-
ple one-pot method. Thus PE coated gold nanoparticles 
show great promise for gene transfection in the future, as 
they can out-perform the current gold standard.
One of the challenges with using PEs is that the strong 
interaction of oppositely charged polymers often leads to 
retardation of the payload release. Changing the pH of 
the PE system can be a way to overcome this problem by 
allowing for a charge reversal of the PE in acidic condi-
tions, leading to release of the siRNA. Using the charge 
reversal method, a study which used PEI/PAH-Cit/PEI/
MUA-AuNPs to release siRNA into cancer cells was able 
to knock-down 80% of Lamin A/C protein expression in 
acidic conditions, whereas the siRNA remained attached 
at a neutral or basic pH [94]. Interestingly, the siRNA was 
released with 14% more efficiency than what is commer-
cially available for this knockdown.
5.3  Photothermal therapy
Hyperthermia is a cancer treatment that has been used 
since the early 1990s [101]. When heat, typically just 
above the physiological temperature, is generated in a 
region of the body, it can lead to damage and destruc-
tion of cells [101]. In Photothermal therapy, the heating is 
more intense and is applied to a specific area though the 
use of NPs, resulting in fewer unwanted side effects com-
pared to the hyperthermic treatment [102]. AuNPs can 
be targeted to a site in the body (i.e. a tumor) by man-
ual injection or through targeted delivery. An external 
laser with a wavelength between 650 and1350 nm is then 
aimed at the specific site where the NPs absorb or scat-
ter that light [103]. This wavelength range is important 
as it can deeply penetrate through healthy tissue to reach 
the AuNPs. The absorbed light causes resonance and is 
converted into heat, which is released to the surrounding 
tissue causing cellular death. Although this concept has 
been shown in several examples, so far PE coated AuNPs 
have not been used. However, PE-coated GNRs have 
been shown to be effective in killing cancer cells in mice 
and cell lines through photothermal therapy [104–107]. 
Compared to GNR, there is little research surrounding 
spherical AuNPs for use in Photothermal therapy, likely 
due to the potentially limited applications, as this therapy 
seeks to penetrate and heat the deeper tissue with near 
infrared (NIR) light. As spherical nanoparticles tend to 
have absorbance between 500 and 550 nm, this does not 
target the NIR region and thus will not penetrate deep 
tissue in the same way as other shapes such as nanorods 
would [108]. Recent studies using AuNP have overcome 
this by using aggregated or clustered nanoparticles, as 
this shifts the absorbance peak to higher wavelengths, 
allowing the wavelength of absorption to be within the 
therapeutic window [109, 110].
5.4  Imaging
Imaging in medicine is an important tool for a number 
of procedures including the localization and diagnosis 
of cancers. The optical properties of gold make it very 
attractive for use as a contrast agent in imaging. So far, 
PE coated GNRs have been used for imaging applications 
rather than spherical AuNPs. A comprehensive review on 
PE GNRs and their imaging capabilities can be found by 
Pissuwan and Niidome and is not within the scope of this 
review [29].
Photoacoustic (PA) imaging and computed tomog-
raphy (CT) are also useful tools in clinical practice for 
imaging. PA imaging is based on the PA effect, where 
pulsed laser light is utilized as probing energy which pro-
duces acoustic waves by thermal expansion. These waves 
are then detected at the surface of the tissue by ultra-
sound and are re-constructed to form an image [111]. 
A study in which PEG-b-poly(ɛ-caprolactone) was teth-
ered to AuNPs showed a strong plasmon coupling effect 
where NIR absorption induced plasmon coupling causing 
an increase in PA signal with high conversion efficiency 
[112]. Similarly AuNP have also shown promise as CT 
contrast agents due to their favourable properties. CT 
images are produced by a combination of X-ray images 
taken at different angles by rotation around an object, 
to form a cross-sectional 3D image known as a CT scan. 
Depending on what is being imaged, contrast agents can 
be used to highlight specific areas such as blood ves-
sels or the tissue structure of organs by attenuating the 
X-rays to improve image quality [113]. Gold nanoparti-
cles are being explored for their use as a contrast agent 
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in CT due to gold having a high atomic number and 
electron density, meaning it has good X-ray attenu-
ation ability. In an experiment using a range of sizes of 
PEGylated AuNP as a contrast agent for CT scans, it was 
found NPs with a size of 13.2 nm and sizes greater than 
34.8 nm performed ~ 20% better in attenuation intensity 
than Idohexal, a common CT contrast agent [114]. Thus 
the area of imaging is extremely promising for PE coated 
AuNP and AuNPs in general.
6  Toxicity
The cytotoxicity of AuNPs is extremely important, espe-
cially if they are being used in the biomedical field. The 
cytotoxicity is dependent on the size, shape, functionali-
sation, surface charge and aggregation of the NPs as well 
as biological factors including the type of cell and the 
uptake mechanisms into the cell [115–119]. PE coatings 
on AuNPs appear to be relatively non-toxic to cells, how-
ever other factors including the type of coating and the 
NP size need to be considered. For example, PAH coated 
18  nm diameter AuNP were compared with CTAB, cit-
rate and poly(acrylic acid) (PAA) coated AuNPs. They 
were exposed to SH-SY5Y (human neuroblastoma) cells 
for 24  h and after incubation all coatings except the 
CTAB coating showed ˃ 95% cell viability. Interestingly, 
when 40  nm PAA coated AuNP were used, cell viabil-
ity dropped considerably to only 10% using the same 
gold concentration [120]. Another study has a similar 
result, where 10 nm diameter PEI coated AuNP showed 
to be biocompatible through in  vitro cytotoxicity stud-
ies, where in gold concentrations of up to 400  μM they 
were shown to be non-toxic to three different cancer cell 
lines (HCT116 colorectal carcinoma, MCF7 breast ade-
nocarcinoma and PC3 prostate adenocarcinoma) [121]. 
Whereas, the 23 nm diameter PEI coated AuNP showed 
a moderate level of cytotoxicity to the same three cancer 
cell lines, with  IC50 results below 80  μM [121]. In both 
experiments the larger nanoparticles proved to be more 
cytotoxic then their smaller counterparts. In contrast to 
this, a recent study has found that in vitro toxicity of PEG 
coated AuNPs is dependent upon size of the particles 
and the dose, with smaller size and higher concentration 
leading to increased cytotoxicity [2]. Similarly in another 
study, 1.4  nm AuNPs were found to be 100 times more 
toxic than 15  nm AuNPs using the same coating [122]. 
Thus there are discrepancies found about size and toxic-
ity throughout the literature which further emphasizes 
the complexity of experimental design, especially when 
testing in vitro.
With many discrepancies found, drawing conclusions 
from the collective body of evidence is difficult as results 
vary depending on a number of experimental factors. 
The toxicity seems to be dependent on the size, surface 
functionalisation, concentration and surface charge of 
the AuNP as well as cell type, serum used, incubation 
time etc. Although there are many studies on AuNP 
toxicity, there are very few studies on the toxicity of PE 
coated AuNP. In order to understand the role PEs play 
in the toxicity space, standardized protocols for both 
in  vivo and in  vitro studies including appropriate cell 
types, assays and dosages would be beneficial to directly 
compare different coatings to determine the toxicity in a 
range of cell types.
7  Conclusions and future outlook
The available literature on PE coated spherical AuNPs 
is limited compared to AuNP with other coatings or its 
PE coated GNR counterpart. The interaction of AuNP 
with cells as well as their uptake is dictated by a range of 
parameters and despite a large body of research, drawing 
conclusions is difficult as there are many inconsistencies 
and complexities to consider. Variables such as the cell 
type, the medium used, AuNP size, concentration and 
charge, among others, can significantly alter the outcome 
and hence care needs to be taken when comparing results 
from literature.
In this review it was found that typically, ≥ 50 nm diam-
eter AuNP have the highest uptake efficiency compared 
to smaller AuNPs. In terms of biomedical applications, 
PE coated AuNPs have shown great potential in areas 
such as SiRNA delivery, imaging and drug delivery. PE 
coated AuNPs have shown to be very effective as siRNA 
carriers—even more so than the current gold standard of 
gene transfection. In addition, proof-of-concept studies 
have indicated they can be used as effective drug deliv-
ery vehicles. Also the use of AuNP in imaging techniques 
such as photoacoustic imaging and computed tomog-
raphy have shown great promise in initial studies, with 
PEGylated AuNPs out-performing Idohexal, a common 
CT contrast agent.
There is however, a large gap of knowledge and more 
research is required to determine how various experi-
mental parameters (size of the PE, salt concentration of 
PE mixture, strength of the attached anion on the AuNPs 
surface and pH) play a role in the deposition of PEs onto 
the AuNPs. Other challenges include how the addition of 
the PE coatings on AuNPs affects the cellular uptake and 
interactions with cells both in vitro and in vivo. A stand-
ardized protocol for both in  vivo and in  vitro studies 
would be beneficial to directly compare different coatings 
and to determine the toxicity in a range of cell types. The 
future outlook for the use of PE coated AuNPs is positive, 
and this review has shown several of the possible uses 
in biomedicine. There is still much research to be con-
ducted to better understand these systems and how each 
individual parameter impacts how they interact with cells 
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but the initial literature in this area shows promise that 
PE coated AuNPs could reach their potential in the bio-
medical field.
Authors’ contributions
MF conducted the literature review and drafted the paper. IK supervised and 
assisted in editing the manuscript. Both authors read and approved the final 
manuscript.
Acknowledgements
The authors would like to thank the Australian Institute of Nuclear Science 
and Engineering (AINSE Ltd) (Award-PGRA) for the top-up scholarship and 
the Australian Government Research Training Program for providing financial 
assistance.
Competing interests
The authors declare that they have no competing interests.





Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
Received: 17 January 2019   Accepted: 20 March 2019
References
 1. N. Elahi, M. Kamali, M.H. Baghersad, Talanta 184, 537–556 (2018)
 2. X. Li, Z. Hu, J. Ma, X. Wang, Y. Zhang, W. Wang, Z. Yuan, Colloids Surf. B 
167, 260–266 (2018)
 3. B.K. Nanjwade, A.B. Sarkar, T. Srichana, in Characterization and biology of 
nanomaterials for drug delivery, ed. by S.S. Mohapatra, S. Ranjan, N. Das-
gupta, R.K. Mishra, S. Thomas (Elsevier, Amsterdam, 2019), pp. 337–350
 4. J. Piella, N.G. Bastús, V. Puntes, Bioconjugate Chem. 28(1), 88–97 (2017)
 5. M.A. Kerr, F. Yan, J. Spectrosc. 2016, 8 (2016)
 6. Y.C. Cao, R. Jin, C.A. Mirkin, Science 297(5586), 1536–1540 (2002)
 7. M.J. Ashley, M.R. Bourgeois, R.R. Murthy, C.R. Laramy, M.B. Ross, R.R. Naik, 
G.C. Schatz, C.A. Mirkin, J. Phys. Chem. C 122(4), 2307–2314 (2018)
 8. L.A. Lane, X. Qian, S. Nie, Chem. Rev. 115(19), 10489–10529 (2015)
 9. I. Fratoddi, I. Venditti, C. Cametti, M.V. Russo, Nano Res. 8(6), 1771–1799 
(2015)
 10. F.-Y. Kong, J.-W. Zhang, R.-F. Li, Z.-X. Wang, W.-J. Wang, W. Wang, Mol-
ecules 22(9), 1445 (2017)
 11. Y.-C. Yeh, B. Creran, V.M. Rotello, Nanoscale 4(6), 1871–1880 (2012)
 12. C. Qu, B. Jing, S. Wang, Y. Zhu, J. Phys. Chem. B 121(37), 8829–8837 
(2017)
 13. G. Decher, Science 277(5330), 1232 (1997)
 14. E. Guzmán, A. Mateos-Maroto, M. Ruano, F. Ortega, R.G. Rubio, Adv. Col-
loid Interface Sci. 249, 290–307 (2017)
 15. A. Figoli, J. Hoinkis, S.A. Altinkaya, J. Bundschuh, Application of nanotech-
nology in membranes for water treatment (CRC Press, Boca Raton, 2017)
 16. F. Caruso, Adv. Mater. 13(1), 11–22 (2001)
 17. P.S. Brown, B. Bhushan, Sci. Rep. 5, 8701 (2015)
 18. C. Elosua, D. Lopez-Torres, M. Hernaez, I.R. Matias, F.J. Arregui, Nanoscale 
Res. Lett. 8(1), 539 (2013)
 19. R.R. Costa, M. Alatorre-Meda, J.F. Mano, Biotechnol. Adv. 33(6, Part 3), 
1310–1326 (2015)
 20. A. Yu, Z. Liang, J. Cho, F. Caruso, Nano Lett. 3(9), 1203–1207 (2003)
 21. V. Shah, C. Malardier-Jugroot, M. Jugroot, Mater. Chem. Phys. 196, 
92–102 (2017)
 22. D.I. Gittins, F. Caruso, J. Phys. Chem. B 105(29), 6846–6852 (2001)
 23. M. Fuller, I. Kӧper, Polymers 10(12), 1336 (2018)
 24. N. Thi Nhat Hang, N. Thi Le Trinh, L. Thi Thanh Tuyen, N. Canh Minh 
Thang, N. Thi Phuong Phong, Adv. Nat. Sci-Nanosci. 7(1), 015006 (2016)
 25. K.S. Lee, M.A. El-Sayed, J. Phys. Chem. B 110(39), 19220–19225 (2006)
 26. C. Yu, J. Irudayaraj, Anal. Chem. 79(2), 572–579 (2007)
 27. J.R. Matthews, C.M. Payne, J.H. Hafner, Langmuir 31(36), 9893–9900 
(2015)
 28. L. An, Y. Wang, Q. Tian, S. Yang, Materials 10(12), 1372 (2017)
 29. D. Pissuwan, T. Niidome, Nanoscale 7(1), 59–65 (2015)
 30. A. Dorris, S. Rucareanu, L. Reven, C.J. Barrett, R.B. Lennox, Langmuir 
24(6), 2532–2538 (2008)
 31. L. Nayef, R. Castiello, M. Tabrizian, Macromol. Biosci. 17(6), 1600535 
(2017)
 32. T.L. Pugh, W. Heller, J. Polym. Sci. 47(149), 219–227 (1960)
 33. S. Ahmed, M.A. Sheraz, I.U. Rehman, AAPS PharmSciTech 14(2), 870–879 
(2013)
 34. S. Maiti, S. Jana, B. Laha, Design and development of new nanocarriers 
(William Andrew Publishing, Norwich, 2018), pp. 223–256
 35. R.R. Netz, J.-F. Joanny, Macromolecules 32(26), 9013–9025 (1999)
 36. R. Sardar, J.S. Shumaker-Parry, J. Am. Chem. Soc. 133(21), 8179–8190 
(2011)
 37. J. Piella, N.G. Bastús, V. Puntes, Chem. Mater. 28(4), 1066–1075 (2016)
 38. H. Xia, Y. Xiahou, P. Zhang, W. Ding, D. Wang, Langmuir 32(23), 
5870–5880 (2016)
 39. J. Turkevich, P.C. Stevenson, J. Hillier, Discuss. Faraday Soc. 11, 55–75 
(1951)
 40. Z. Xiang, K. Wang, W. Zhang, S.W. Teh, A. Peli, P.L. Mok, A. Higuchi, S. 
Suresh Kumar, J. Cluster Sci. 29(1), 1–7 (2018)
 41. G. Frens, Nat. Phys Sci. 241, 20–22 (1973)
 42. M. Brust, M. Walker, D. Bethell, D.J. Schiffrin, R. Whyman, J. Chem. Soc. 
Chem. Commun. 7, 801–802 (1994)
 43. J.D.S. Newman, G.J. Blanchard, Langmuir 22(13), 5882–5887 (2006)
 44. H. Dozol, G. Mériguet, B. Ancian, V. Cabuil, H. Xu, D. Wang, A. Abou-
Hassan, J. Phys. Chem. C 117(40), 20958–20966 (2013)
 45. S. Arghya, G. Manoj, S. Pragya, D. Manab, B. Utpal, Adv. Nat. Sci-Nanosci. 
7(2), 025005 (2016)
 46. Y. Jang, N. Lee, J. Kim, Y. Park, Y. Piao, Nanomaterials 8(4), 252 (2018)
 47. V. Gopinath, S. Priyadarshini, D. MubarakAli, M.F. Loke, N. Thajuddin, N.S. 
Alharbi, T. Yadavalli, M. Alagiri, J. Vadivelu, Arab J. Chem. 10, 1107–1117 
(2017)
 48. S. Labala, P.K. Mandapalli, A. Kurumaddali, V.V.K. Venuganti, Mol. Pharm. 
12(3), 878–888 (2015)
 49. M. Ortega-Munoz, M.D. Giron-Gonzalez, R. Salto-Gonzalez, A.B. 
Jodar-Reyes, S.E. De Jesus, F.J. Lopez-Jaramillo, F. Hernandez-Mateo, F. 
Santoyo-Gonzalez, Chem. Asian J. 11(23), 3365–3375 (2016)
 50. E.C. Dreaden, A.M. Alkilany, X. Huang, C.J. Murphy, M.A. El-Sayed, Chem. 
Soc. Rev. 41(7), 2740–2779 (2012)
 51. X. Xie, S. Xu, P. Pi, J. Cheng, X. Wen, X. Liu, S. Wang, AlChE J. 64(3), 
810–821 (2018)
 52. B. Masereel, M. Dinguizli, C. Bouzin, N. Moniotte, O. Feron, B. Gallez, T. 
Vander Borght, C. Michiels, S. Lucas, J. Nanopart. Res. 13(4), 1573–1580 
(2011)
 53. N. Reum, C. Fink-Straube, T. Klein, R.W. Hartmann, C.-M. Lehr, M. Schnei-
der, Langmuir 26(22), 16901–16908 (2010)
 54. Y. Lee, S.H. Lee, J.S. Kim, A. Maruyama, X. Chen, T.G. Park, J. Controlled 
Release 155(1), 3–10 (2011)
 55. J. Homola, S.S. Yee, G. Gauglitz, Sens Actuators B Chem. 54(1), 3–15 
(1999)
 56. A. Vincenzo, P. Roberto, F. Marco, M.M. Onofrio, I. Maria Antonia, J. Phys.: 
Condens. Matter 29(20), 203002 (2017)
 57. T. Felicia, B. Monica, B. Lucian, A. Simion, Nanotechnology 18(25), 
255702 (2007)
 58. H.-H. Chang, C.J. Murphy, Chem. Mater. 30(4), 1427–1435 (2018)
 59. G. Mie, Ann. Phys. 330(3), 377–445 (1908)
 60. H. Aldewachi, T. Chalati, M.N. Woodroofe, N. Bricklebank, B. Sharrack, P. 
Gardiner, Nanoscale 10(1), 18–33 (2018)
 61. K.S. Mayya, B. Schoeler, F. Caruso, Adv. Funct. Mater. 13(3), 183–188 
(2003)
 62. S. Pollastri, A.F. Gualtieri, M.L. Gualtieri, M. Hanuskova, A. Cavallo, G. 
Gaudino, J. Hazard. Mater. 276, 469–479 (2014)
Page 10 of 10Fuller and Köper  Nano Convergence            (2019) 6:11 
 63. S. Spriano, V. Sarath Chandra, A. Cochis, F. Uberti, L. Rimondini, E. Ber-
tone, A. Vitale, C. Scolaro, M. Ferrari, F. Cirisano, G. Gautier di Confiengo, 
S. Ferraris, Mater. Sci. Eng. C 74, 542–555 (2017)
 64. T. Luxbacher, (Anton Paar GmbH, Austria, 2014)
 65. J.A.A. Junior, J.B. Baldo, New J. Glass Ceramics 04(02), 9 (2014)
 66. S. Behzadi, V. Serpooshan, W. Tao, M.A. Hamaly, M.Y. Alkawareek, E.C. 
Dreaden, D. Brown, A.M. Alkilany, O.C. Farokhzad, M. Mahmoudi, Chem. 
Soc. Rev. 46(14), 4218–4244 (2017)
 67. X. Cheng, X. Tian, A. Wu, J. Li, J. Tian, Y. Chong, Z. Chai, Y. Zhao, C. Chen, 
C. Ge, ACS Appl. Mater. Interfaces 7(37), 20568–20575 (2015)
 68. C. Corbo, R. Molinaro, A. Parodi, N.E.T. Furman, F. Salvatore, E. Tasciotti, 
Nanomedicine 11(1), 81–100 (2016)
 69. A. Elbakry, A. Zaky, R. Liebl, R. Rachel, A. Goepferich, M. Breunig, Nano 
Lett. 9(5), 2059–2064 (2009)
 70. F. Charbgoo, M. Nejabat, K. Abnous, F. Soltani, S.M. Taghdisi, M. Alibo-
landi, W. Thomas Shier, T.W.J. Steele, M. Ramezani, J. Controlled Release 
272, 39–53 (2018)
 71. J.M. Blander, R. Medzhitov, Nat. Immunol. 7(10), 1029–1035 (2006)
 72. M.A. Dobrovolskaia, S.E. McNeil, Nat Nano 2(8), 469–478 (2007)
 73. S.D. Conner, S.L. Schmid, Nature 422(6927), 37–44 (2003)
 74. A.U. Aderem, Annu. Rev. Immunol. 17(1), 593–623 (1999)
 75. N. Oh, J.-H. Park, Int. J. Nanomed. 9(Suppl 1), 51–63 (2014)
 76. S.D. Xiang, A. Scholzen, G. Minigo, C. David, V. Apostolopoulos, P.L. Mot-
tram, M. Plebanski, Methods 40(1), 1–9 (2006)
 77. F. Fekri, R.C. Delos Santos, R. Karshafian, C.N. Antonescu, PLoS ONE 11(6), 
e0156754 (2016)
 78. B.D. Chithrani, W.C.W. Chan, Nano Lett. 7(6), 1542–1550 (2007)
 79. H. Gao, W. Shi, L.B. Freund, Proc. Natl. Acad. Sci. U. S. A. 102(27), 
9469–9474 (2005)
 80. V.P. Torchilin, Smart pharmaceutical nanocarriers (Imperial College Press, 
New Jersey, 2015)
 81. L. Shang, K. Nienhaus, G.U. Nienhaus, J. Nanobiotechnology 12(1), 5 
(2014)
 82. A.C. Wong, D.W. Wright, Small 12(40), 5592–5600 (2016)
 83. C.C. Fleischer, C.K. Payne, Acc. Chem. Res. 47(8), 2651–2659 (2014)
 84. A.M. Alkilany, P.K. Nagaria, C.R. Hexel, T.J. Shaw, C.J. Murphy, M.D. Wyatt, 
Small 5(6), 701–708 (2009)
 85. C.M. Goodman, C.D. McCusker, T. Yilmaz, V.M. Rotello, Bioconjugate 
Chem. 15(4), 897–900 (2004)
 86. S. Nambiar, E. Osei, A. Fleck, J. Darko, A.J. Mutsaers, S. Wettig, Appl Nano-
science 8(3), 347–357 (2018)
 87. S. Huo, S. Jin, X. Ma, X. Xue, K. Yang, A. Kumar, P.C. Wang, J. Zhang, Z. Hu, 
X.-J. Liang, ACS Nano 8(6), 5852–5862 (2014)
 88. J.A. Ryan, K.W. Overton, M.E. Speight, C.N. Oldenburg, L. Loo, W. 
Robarge, S. Franzen, D.L. Feldheim, Anal. Chem. 79(23), 9150–9159 
(2007)
 89. M. Kodiha, Y.M. Wang, E. Hutter, D. Maysinger, U. Stochaj, Theranostics 
5(4), 357–370 (2015)
 90. R. Shukla, V. Bansal, M. Chaudhary, A. Basu, R.R. Bhonde, M. Sastry, Lang-
muir 21(23), 10644–10654 (2005)
 91. N. Pernodet, X. Fang, Y. Sun, A. Bakhtina, A. Ramakrishnan, J. Sokolov, A. 
Ulman, M. Rafailovich, Small 2(6), 766–773 (2006)
 92. G. Han, P. Ghosh, V.M. Rotello, Nanomedicine (Lond) 2(1), 113–123 
(2007)
 93. S.G. Elci, Y. Jiang, B. Yan, S.T. Kim, K. Saha, D.F. Moyano, G. Yesilbag Tonga, 
L.C. Jackson, V.M. Rotello, R.W. Vachet, ACS Nano 10(5), 5536–5542 
(2016)
 94. S. Guo, Y. Huang, Q. Jiang, Y. Sun, L. Deng, Z. Liang, Q. Du, J. Xing, Y. Zhao, 
P.C. Wang, A. Dong, X.-J. Liang, ACS Nano 4(9), 5505–5511 (2010)
 95. A. Lamprecht, N. Ubrich, H. Yamamoto, U. Schafer, H. Takeuchi, P. Main-
cent, Y. Kawashima, C.M. Lehr, J. Pharmacol. Exp. Ther. 299(2), 775–781 
(2001)
 96. R. Singh, J.W. Lillard, Exp. Mol. Pathol. 86(3), 215–223 (2009)
 97. T.S. Zatsepin, Y.V. Kotelevtsev, V. Koteliansky, Int J. Nanomed. 11, 
3077–3086 (2016)
 98. M. Singh, D.C.C. Harris-Birtill, S.R. Markar, G.B. Hanna, D.S. Elson, 
Nanomed Nanotechnol. 11(8), 2083–2098 (2015)
 99. Y.N. Konan, R. Gurny, E. Allemann, J. Photochem. Photobiol. B 66(2), 
89–106 (2002)
 100. R. Kanasty, J.R. Dorkin, A. Vegas, D. Anderson, Nat. Mater. 12(11), 
967–977 (2013)
 101. N.S. Abadeer, C.J. Murphy, J. Phys. Chem. C 120(9), 4691–4716 (2016)
 102. E.S. Day, J.G. Morton, J.L. West, J. Biomech. Eng. 131(7), 074001 (2009)
 103. E. S. D. Rache S. Riley, Wiley Interdisclip Rev Nanomed Nanobiotechnol. 
9 (4) (2017)
 104. X. Huang, I.H. El-Sayed, W. Qian, M.A. El-Sayed, J. Am. Chem. Soc. 128(6), 
2115–2120 (2006)
 105. D.K. Kirui, S. Krishnan, A.D. Strickland, C.A. Batt, Macromol. Biosci. 11(6), 
779–788 (2011)
 106. B. Wang, J.-H. Wang, Q. Liu, H. Huang, M. Chen, K. Li, C. Li, X.-F. Yu, P.K. 
Chu, Biomaterials 35(6), 1954–1966 (2014)
 107. J. Wang, B. Dong, B. Chen, Z. Jiang, H. Song, Dalton Trans. 41(36), 11134–
11144 (2012)
 108. Z. Bao, X. Liu, Y. Liu, H. Liu, K. Zhao, Asian. J. Pharm. Sci. 11(3), 349–364 
(2016)
 109. X. Cheng, R. Sun, L. Yin, Z. Chai, H. Shi, M. Gao, Adv. Mater. 29(6), 
1604894 (2017)
 110. T. Curry, R. Kopelman, M. Shilo, R. Popovtzer, Contrast Media Mol. Imag-
ing 9(1), 53–61 (2014)
 111. S. Mallidi, S. Kim, A. Karpiouk, P.P. Joshi, K. Sokolov, S. Emelianov, Photoa-
coustics 3(1), 26–34 (2015)
 112. P. Huang, J. Lin, W. Li, P. Rong, Z. Wang, S. Wang, X. Wang, X. Sun, M. 
Aronova, G. Niu, R.D. Leapman, Z. Nie, X. Chen, Angew. Chem. Int. Ed. 
52(52), 13958–13964 (2013)
 113. H. Lusic, M.W. Grinstaff, Chem. Rev. (2013). https ://doi.org/10.1021/
cr200 358s
 114. Y. Dou, Y. Guo, X. Li, X. Li, S. Wang, L. Wang, G. Lv, X. Zhang, H. Wang, X. 
Gong, J. Chang, ACS Nano 10(2), 2536–2548 (2016)
 115. A.M. Alkilany, C.J. Murphy, J. Nanopart. Res. 12(7), 2313–2333 (2010)
 116. M. Sathishkumar, S. Pavagadhi, A. Mahadevan, R. Balasubramanian, 
Ecotoxicol. Environ. Saf. 114, 232–240 (2015)
 117. Y. Zhang, D. Xu, W. Li, J. Yu, Y. Chen, J Nanomater. 2012, 7 (2012)
 118. S. Vial, R.L. Reis, J.M. Oliveira, Curr. Opin. Solid State Mater. Sci. 21(2), 
92–112 (2017)
 119. A. Woźniak, A. Malankowska, G. Nowaczyk, B.F. Grześkowiak, K. Tuśnio, R. 
Słomski, A. Zaleska-Medynska, S. Jurga, J. Mater. Sci. Mater. Med. 28(6), 
92 (2017)
 120. K.A. Moore, K.M. Pate, D.D. Soto-Ortega, S. Lohse, N. van der Munnik, M. 
Lim, K.S. Jackson, V.D. Lyles, L. Jones, N. Glassgow, V.M. Napumecheno, S. 
Mobley, M.J. Uline, R. Mahtab, C.J. Murphy, M.A. Moss, J. Biol. Eng. 11(1), 
5 (2017)
 121. M. Bouché, S. Fournel, A. Kichler, T. Selvam, J.-L. Gallani, S. Bellemin-
Laponnaz, Eur. J. Inorg. Chem. 2018(25), 2972–2975 (2018)
 122. Y. Pan, A. Leifert, D. Ruau, S. Neuss, J. Bornemann, G. Schmid, W. Brandau, 
U. Simon, W. Jahnen-Dechent, Small 5(18), 2067–2076 (2009)
